We used a drug screen to identify a variety of FDA-approved drugs that can be repurposed to deplete tumor PDL1 and phenocopy important genetic PDL1 depletion outcomes, including suppressing mTORC1 and tumor stemness, and promoting tumor autophagy. Here, CD274 is linked to neoplasm.